Literature DB >> 24917702

The floppy iris syndrome - what urologists and ophthalmologists need to know.

Faruquz Zaman1, Christian Bach1, Islam Junaid1, Athanasios G Papatsoris1, Jhumur Pati1, Junaid Masood1, Noor Buchholz1.   

Abstract

INTRODUCTION: Benign prostatic hyperplasia (BPH) and cataract formation are common in older people. Medical management of symptomatic BPH is often preferred to surgical treatment as surgery increases the risk of morbidities, whereas, surgery is the main form of treatment to restore sight in patient with cataract. The clinical treatment of BPH is either alpha-1 adrenergic antagonist alone or combination of alpha reductase inhibitor and alpha adrenergic receptor (AR) antagonist. There are four alpha-AR antagonists currently available to treat BPH. The uroselective alpha-blocker tamsulosin is the most commonly used drug among all. Studies showed that the majority of the patients who develop intraoperative floppy iris syndrome (IFIS) were on tamsulosin. Women are more likely to develop cataract than men and some recent studies showed that tamsulosin is effective in treating female lower urinary tract symptoms and thereby can cause IFIS during cataract surgery. EVIDENCE ACQUISITION: We performed a critical review of the published articles and abstracts on association of IFIS with alpha-blockers and other medications as well as other medical conditions. EVIDENCE SYNTHESIS: Tamsulosin is the most common cause of formation of IFIS. However, not all patients given tamsulosin develop IFIS and cases have been reported without any tamsulosin treatment.
CONCLUSION: Tamsulosin is a recognized cause to impede mydriasis and lead to IFIS during cataract surgery. Urologist should collaborate with their ophthalmology colleagues and general practitioner during prescribing tamsulosin in patients with history of cataract or waiting for planned cataract surgery. The increasing life expectancy and growth of older people will increase the number of men and women who suffer from lower urinary tract symptoms as well as cataract. Therefore, further research and studies are required to properly understand the relation of alpha blockers and IFIS.

Entities:  

Keywords:  Alpha adrenergic blocker; Benign prostatic hyperplasia; Cataract complication; Floppy iris syndrome; Tamsulosin

Year:  2012        PMID: 24917702      PMCID: PMC3783304          DOI: 10.1159/000338861

Source DB:  PubMed          Journal:  Curr Urol        ISSN: 1661-7649


  35 in total

1.  Antipsychotic agent as an etiologic agent of IFIS.

Authors:  Edward Pringle; Richard Packard
Journal:  J Cataract Refract Surg       Date:  2005-12       Impact factor: 3.351

2.  Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part I.

Authors:  A Leonardi; J P Hieble; L Guarneri; D P Naselsky; E Poggesi; G Sironi; A C Sulpizio; R Testa
Journal:  J Pharmacol Exp Ther       Date:  1997-06       Impact factor: 4.030

3.  A difference in mode of antagonism between optical isomers of a potent selective alpha 1-adrenoceptor blocker (YM-12617) and norepinephrine in isolated rabbit iris dilator and aorta.

Authors:  I Takayanagi; F Konno; H Kameda; H Kubo; A Furukawa; T Toyoda
Journal:  Jpn J Pharmacol       Date:  1986-12

Review 4.  alpha(1)-Adrenergic receptor antagonists and the iris: new mechanistic insights into floppy iris syndrome.

Authors:  Debra A Schwinn; Natalie A Afshari
Journal:  Surv Ophthalmol       Date:  2006 Sep-Oct       Impact factor: 6.048

5.  Pharmacological studies of 8-OH-DPAT-induced pupillary dilation in anesthetized rats.

Authors:  Yongxin Yu; Andrew G Ramage; Michael C Koss
Journal:  Eur J Pharmacol       Date:  2004-04-12       Impact factor: 4.432

6.  Buspirone, but not sumatriptan, induces miosis in humans: relevance for a serotoninergic pupil control.

Authors:  M Fanciullacci; R Sicuteri; M Alessandri; P Geppetti
Journal:  Clin Pharmacol Ther       Date:  1995-03       Impact factor: 6.875

7.  Bothersome urinary symptoms and disease-specific quality of life in patients with benign prostatic obstruction.

Authors:  Helén Marklund-Bau; Ulla Edéll-Gustafsson; Anders Spångberg
Journal:  Scand J Urol Nephrol       Date:  2007

8.  Intraoperative floppy-iris syndrome associated with alpha1-adrenoreceptors: comparison of tamsulosin and alfuzosin.

Authors:  Marie-Claude Blouin; Julie Blouin; Sylvie Perreault; André Lapointe; Alice Dragomir
Journal:  J Cataract Refract Surg       Date:  2007-07       Impact factor: 3.351

9.  Functional identification of alpha 1-adrenoceptor subtypes in human prostate: comparison with those in rat vas deferens and spleen.

Authors:  C M Teng; J H Guh; F N Ko
Journal:  Eur J Pharmacol       Date:  1994-11-14       Impact factor: 4.432

10.  Clinical features, complications, and incidence of intraoperative floppy iris syndrome in patients taking tamsulosin.

Authors:  T Takmaz; I Can
Journal:  Eur J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 2.597

View more
  5 in total

1.  Phytotherapy and intraoperative floppy iris syndrome: the implications.

Authors:  M Tsatsos; C MacGregor; I Athanasiadis; M Moschos; A Mataftsi; N Ziakas
Journal:  Eye (Lond)       Date:  2017-03-03       Impact factor: 3.775

2.  Silodosin as a predisposing factor of intraoperative floppy iris syndrome (IFIS): an observational propensity score-matching cohort study.

Authors:  Chrysanthos D Christou; Marianna Kourouklidou; Asimina Mataftsi; Eirini Oustoglou; Nikolaos Ziakas; Argyrios Tzamalis
Journal:  Int Ophthalmol       Date:  2021-10-05       Impact factor: 2.031

Review 3.  Ten years of intraoperative floppy iris syndrome in the era of α-blockers.

Authors:  Andreas Lunacek; Badereddin Mohamad Al-Ali; Christian Radmayr; Maria Weber; Wolfgang Horninger; Oliver Findl; Eugen Plas
Journal:  Cent European J Urol       Date:  2017-12-06

Review 4.  Intraoperative Floppy Iris Syndrome: Updated Perspectives.

Authors:  Chrysanthos D Christou; Argyrios Tzamalis; Ioannis Tsinopoulos; Nikolaos Ziakas
Journal:  Clin Ophthalmol       Date:  2020-02-20

Review 5.  Current and Emerging Classes of Pharmacological Agents for the Management of Hypertension.

Authors:  Utkarsh Ojha; Sanjay Ruddaraju; Navukkarasu Sabapathy; Varun Ravindran; Pitchaya Worapongsatitaya; Jeesanul Haq; Raihan Mohammed; Vinod Patel
Journal:  Am J Cardiovasc Drugs       Date:  2021-12-08       Impact factor: 3.283

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.